0J8Z Stock Overview
Illumina, Inc. offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 0J8Z from our risk checks.
Illumina, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$113.75 |
| 52 Week High | US$212.66 |
| 52 Week Low | US$89.21 |
| Beta | 1.19 |
| 1 Month Change | -12.70% |
| 3 Month Change | -20.54% |
| 1 Year Change | -44.61% |
| 3 Year Change | -69.68% |
| 5 Year Change | -62.79% |
| Change since IPO | -53.54% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0J8Z | GB Life Sciences | GB Market | |
|---|---|---|---|
| 7D | -7.8% | 6.7% | 2.0% |
| 1Y | -44.6% | -42.5% | 4.5% |
Return vs Industry: 0J8Z underperformed the UK Life Sciences industry which returned -42.5% over the past year.
Return vs Market: 0J8Z underperformed the UK Market which returned 4.5% over the past year.
Price Volatility
| 0J8Z volatility | |
|---|---|
| 0J8Z Average Weekly Movement | 5.7% |
| Life Sciences Industry Average Movement | 5.8% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.4% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: 0J8Z's share price has been volatile over the past 3 months.
Volatility Over Time: 0J8Z's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 10,615 | Jacob Thaysen | www.illumina.com |
Illumina, Inc. offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.
Illumina, Inc. Fundamentals Summary
| 0J8Z fundamental statistics | |
|---|---|
| Market cap | US$17.97b |
| Earnings (TTM) | -US$1.29b |
| Revenue (TTM) | US$4.49b |
4.0x
P/S Ratio-13.9x
P/E RatioIs 0J8Z overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0J8Z income statement (TTM) | |
|---|---|
| Revenue | US$4.49b |
| Cost of Revenue | US$1.54b |
| Gross Profit | US$2.95b |
| Other Expenses | US$4.24b |
| Earnings | -US$1.29b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -8.10 |
| Gross Margin | 65.72% |
| Net Profit Margin | -28.71% |
| Debt/Equity Ratio | 26.0% |
How did 0J8Z perform over the long term?
See historical performance and comparison